Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Alterations in Respiration II01:30

Alterations in Respiration II

There are numerous types of normal and abnormal respiration. Based on ventilatory movements, breathing patterns are classified as regular, deep, or shallow. Examples include Biot's breathing, Cheyne-Stokes respiration, Kussmaul's breathing, hyperventilation, and hypoventilation. Each pattern is clinically significant and aids in evaluating patients.
In Biot's breathing, the respiratory rate and depth are irregular, alternating between periods of deep gasping and apnea. Common causes include...
Repressible Operon: trp Operon01:21

Repressible Operon: trp Operon

The trp operon in Escherichia coli exemplifies a repressible operon. It regulates the synthesis of tryptophan through repressor-mediated transcriptional control and attenuation. This dual regulatory mechanism ensures tryptophan biosynthesis occurs only when needed, conserving cellular resources.Structure of the trp OperonThe trp operon consists of five structural genes (trpE, trpD, trpC, trpB, and trpA) that encode enzymes for tryptophan biosynthesis. These genes are transcribed as a single...
Proofreading01:43

Proofreading

Synthesis of new DNA molecules starts when DNA polymerase links nucleotides together in a sequence that is complementary to the template DNA strand. DNA polymerase has a higher affinity for the correct base to ensure fidelity in DNA replication. The DNA polymerase furthermore proofreads during replication, using an exonuclease domain that cuts off incorrect nucleotides from the nascent DNA strand.Errors during Replication Are Corrected by the DNA Polymerase EnzymeGenomic DNA is synthesized in...
Proofreading01:43

Proofreading

Synthesis of new DNA molecules starts when DNA polymerase links nucleotides together in a sequence that is complementary to the template DNA strand. DNA polymerase has a higher affinity for the correct base to ensure fidelity in DNA replication. The DNA polymerase furthermore proofreads during replication, using an exonuclease domain that cuts off incorrect nucleotides from the nascent DNA strand.Errors during Replication Are Corrected by the DNA Polymerase EnzymeGenomic DNA is synthesized in...
Proofreading01:31

Proofreading

Synthesis of new DNA molecules is carried out by the enzyme DNA polymerase, which adds nucleotides on the daughter strand complementary to the template DNA strand. DNA polymerase has a higher affinity to add the correct base and ensures fidelity during DNA replication. Furthermore,  it exhibits proofreading activity during replication, using an exonuclease domain that cuts off incorrect nucleotides from the nascent DNA strand.
Errors During Replication are Corrected by the DNA Polymerase Enzyme

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Endotypic trait responses to 12-month tirzepatide treatment for an obese patient with obstructive sleep apnea: a case report.

Obesity facts·2026
Same journal

Targeting Inflammation in Obesity and the Cardiovascular-Kidney-Metabolic (CKM) Syndrome Spectrum: A Narrative Review.

Obesity facts·2026
Same journal

Erratum.

Obesity facts·2026
Same journal

Addressing weight stigma in healthcare settings using an obesity checklist: a mixed-method development study.

Obesity facts·2026
Same journal

Impact of an intensive lifestyle camp on anthropometry and quality of life in vulnerable children: A 3-year follow-up of a nonrandomized clinical trial.

Obesity facts·2026
Same journal

Baseline and follow-up association between adiposity and renal function: data from the ILERVAS cohort.

Obesity facts·2026
See all related articles

Related Experiment Video

Updated: Jun 25, 2026

Transcorporal Artificial Urinary Sphincter Cuff Placement in a Case Requiring Revision for Urethral Atrophy
03:25

Transcorporal Artificial Urinary Sphincter Cuff Placement in a Case Requiring Revision for Urethral Atrophy

Published on: June 16, 2022

Erratum

    Obesity Facts
    |June 23, 2026
    PubMed
    Summary
    This summary is machine-generated.

    Semaglutide significantly reduced BMI in children and young people with severe obesity, showing sustained effects up to 18 months. This GLP-1 receptor agonist offers a promising treatment for pediatric obesity and its complications.

    Related Experiment Videos

    Last Updated: Jun 25, 2026

    Transcorporal Artificial Urinary Sphincter Cuff Placement in a Case Requiring Revision for Urethral Atrophy
    03:25

    Transcorporal Artificial Urinary Sphincter Cuff Placement in a Case Requiring Revision for Urethral Atrophy

    Published on: June 16, 2022

    Area of Science:

    • Pediatric Endocrinology
    • Metabolic Disorders
    • Pharmacology

    Background:

    • Severe obesity in children and young people (CYP) is associated with significant health complications.
    • Specialist weight management clinics are crucial for managing complex pediatric obesity cases.
    • GLP-1 receptor agonists are emerging as a therapeutic option for obesity management.

    Purpose of the Study:

    • To evaluate the efficacy of semaglutide in reducing %BMIp95 in CYP with severe and complicated obesity.
    • To assess the impact of semaglutide on obesity-related comorbidities in a pediatric population.
    • To compare the outcomes of semaglutide treatment with matched controls in a real-world setting.

    Main Methods:

    • A cohort of 406 CYP receiving semaglutide was matched with 787 comparator patients from 35 specialist weight management clinics in England.
    • Baseline characteristics, including %BMIp95 and obesity-related complications, were recorded.
    • Changes in %BMIp95 and BMI were assessed at 6, 12, and 18 months post-treatment initiation.

    Main Results:

    • The semaglutide group showed significant reductions in %BMIp95 at 6, 12, and 18 months (13.8%, 19.0%, and 22.9% lower, respectively) compared to matched comparators.
    • Corresponding relative reductions in BMI were 7.4%, 10.2%, and 11.2% at the same time points.
    • The study cohort presented with a high burden of comorbidities, including metabolic dysfunction-associated steatotic liver disease, dysglycaemia, obstructive sleep apnoea, hypertension, and polycystic ovary syndrome.

    Conclusions:

    • Semaglutide demonstrates significant efficacy in reducing BMI in CYP with severe obesity.
    • The observed reductions in %BMIp95 and BMI are sustained up to 18 months.
    • Semaglutide represents a valuable therapeutic option for managing severe and complicated obesity in pediatric populations.